Evolus Inc Stock Analysis

EOLS Stock  USD 9.58  0.01  0.10%   
Evolus Inc is overvalued with Real Value of 8.05 and Target Price of 23.57. The main objective of Evolus stock analysis is to determine its intrinsic value, which is an estimate of what Evolus Inc is worth, separate from its market price. There are two main types of Evolus' stock analysis: fundamental analysis and technical analysis.
The Evolus stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Evolus is usually not traded on Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday. Evolus Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Evolus Stock Analysis Notes

About 85.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.89. Evolus Inc had not issued any dividends in recent years. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 174 people. To learn more about Evolus Inc call David Moatazedi at 949 284 4555 or check out https://www.evolus.com.

Evolus Inc Investment Alerts

Evolus Inc generated a negative expected return over the last 90 days
Evolus Inc has high historical volatility and very poor performance
The company reported the previous year's revenue of 266.27 M. Net Loss for the year was (50.42 M) with profit before overhead, payroll, taxes, and interest of 188.46 M.
Evolus Inc currently holds about 84.48 M in cash with (18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51.
Over 85.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: Evolus to Report Second Quarter Financial Results on August 5, 2025 EOLS Stock News

Evolus Inc Upcoming and Recent Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Evolus Largest EPS Surprises

Earnings surprises can significantly impact Evolus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-03-04
2024-12-310.02230.0139-0.008437 
2024-07-31
2024-06-30-0.05-0.040.0120 
2024-05-07
2024-03-31-0.1-0.090.0110 
View All Earnings Estimates

Evolus Environmental, Social, and Governance (ESG) Scores

Evolus' ESG score is a quantitative measure that evaluates Evolus' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Evolus' operations that may have significant financial implications and affect Evolus' stock price as well as guide investors towards more socially responsible investments.

Evolus Stock Institutional Investors

Shares
Stonepine Capital Management Llc2025-03-31
1.1 M
Soleus Capital Management, L.p.2025-03-31
1.1 M
Schroder Investment Management Group2025-03-31
M
Nuveen, Llc2025-03-31
M
Soros Fund Management Llc2025-03-31
995.5 K
Ubs Group Ag2025-03-31
953.7 K
Great Point Partners Llc2025-03-31
944.7 K
Rice Hall James & Associates, Llc2025-03-31
921.4 K
D. E. Shaw & Co Lp2025-03-31
877.1 K
Tang Capital Management Llc2025-03-31
M
Blackrock Inc2025-03-31
4.3 M
Note, although Evolus' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Evolus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 617.68 M.

Evolus Profitablity

The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.19.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.31)(0.33)
Return On Capital Employed(0.20)(0.21)
Return On Assets(0.22)(0.23)
Return On Equity(9.13)(8.67)

Management Efficiency

Evolus Inc has return on total asset (ROA) of (0.0936) % which means that it has lost $0.0936 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.4946) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.21 in 2025. At this time, Evolus' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 6.9 M in 2025, whereas Net Tangible Assets are likely to drop (62 M) in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 0.09  0.08 
Tangible Book Value Per Share(1.04)(1.09)
Enterprise Value Over EBITDA(29.11)(27.65)
Price Book Value Ratio 123.99  130.19 
Enterprise Value Multiple(29.11)(27.65)
Price Fair Value 123.99  130.19 
Enterprise Value727.7 M764.1 M
The decision-making processes within Evolus are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Operating Margin
(0.19)
Profit Margin
(0.20)
Beta
0.976
Return On Assets
(0.09)
Return On Equity
(9.49)

Technical Drivers

As of the 23rd of July, Evolus shows the Mean Deviation of 2.23, variance of 10.47, and Standard Deviation of 3.24. Evolus Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Evolus Inc variance and potential upside to decide if Evolus Inc is priced favorably, providing market reflects its regular price of 9.58 per share. Given that Evolus has information ratio of (0.11), we urge you to verify Evolus Inc's prevailing market performance to make sure the company can sustain itself at a future point.

Evolus Inc Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Evolus middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Evolus Inc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Evolus Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evolus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evolus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evolus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
David Moatazedi over a month ago
Disposition of 16582 shares by David Moatazedi of Evolus at 9.8935 subject to Rule 16b-3
 
White Albert G Iii over a month ago
Acquisition by White Albert G Iii of 20000 shares of Evolus at 9.45 subject to Rule 16b-3
 
Avelar Rui over two months ago
Disposition of 3385 shares by Avelar Rui of Evolus at 9.8661 subject to Rule 16b-3
 
David Moatazedi over two months ago
Disposition of 15787 shares by David Moatazedi of Evolus at 9.8661 subject to Rule 16b-3
 
David Moatazedi over three months ago
Disposition of 6251 shares by David Moatazedi of Evolus at 12.4 subject to Rule 16b-3
 
David Moatazedi over three months ago
Disposition of 103376 shares by David Moatazedi of Evolus at 13.255 subject to Rule 16b-3
 
Parschauer Karah Herdman over three months ago
Disposition of 12888 shares by Parschauer Karah Herdman of Evolus at 12.99 subject to Rule 16b-3
 
Parschauer Karah Herdman over three months ago
Acquisition by Parschauer Karah Herdman of 11146 shares of Evolus at 13.58 subject to Rule 16b-3
 
Gill David N over three months ago
Acquisition by Gill David N of 8293 shares of Evolus subject to Rule 16b-3
 
Avelar Rui over three months ago
Disposition of 2252 shares by Avelar Rui of Evolus at 10.8519 subject to Rule 16b-3
 
David Moatazedi over six months ago
Disposition of 10502 shares by David Moatazedi of Evolus at 10.8519 subject to Rule 16b-3
 
Parschauer Karah Herdman over six months ago
Acquisition by Parschauer Karah Herdman of 11789 shares of Evolus at 10.25 subject to Rule 16b-3

Evolus Predictive Daily Indicators

Evolus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evolus stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evolus Corporate Filings

F4
16th of June 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
10th of June 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
6th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
27th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
15th of May 2025
Other Reports
ViewVerify
F4
14th of May 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
7th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
5th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Evolus Forecast Models

Evolus' time-series forecasting models are one of many Evolus' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evolus' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Evolus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evolus prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evolus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Evolus. By using and applying Evolus Stock analysis, traders can create a robust methodology for identifying Evolus entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.19)(0.20)
Operating Profit Margin(0.13)(0.14)
Net Loss(0.19)(0.20)
Gross Profit Margin 0.68  0.74 

Current Evolus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evolus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evolus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
23.57Strong Buy7Odds
Evolus Inc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Evolus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Evolus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evolus Inc, talking to its executives and customers, or listening to Evolus conference calls.
Evolus Analyst Advice Details

Evolus Stock Analysis Indicators

Evolus Inc stock analysis indicators help investors evaluate how Evolus stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evolus shares will generate the highest return on investment. By understating and applying Evolus stock analysis, traders can identify Evolus position entry and exit signals to maximize returns.
Begin Period Cash Flow62.8 M
Long Term Debt121.5 M
Common Stock Shares Outstanding62 M
Total Stockholder Equity5.5 M
Total Cashflows From Investing Activities-4.8 M
Tax Provision664 K
Property Plant And Equipment Net10.4 M
Cash And Short Term Investments87 M
Cash87 M
Accounts Payable9.2 M
Net Debt43 M
50 Day M A9.578
Total Current Liabilities63 M
Other Operating Expenses289.2 M
Non Current Assets Total81.2 M
Forward Price Earnings158.7302
Non Currrent Assets Other858 K
Stock Based Compensation22.3 M

Additional Tools for Evolus Stock Analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.